1
|
Fain O, Du-Thanh A, Gobert D, Launay D, Inhaber N, Boudjemia K, Aubineau M, Sobel A, Boccon-Gibod I, Weiss L, Bouillet L. Long-term prophylaxis with lanadelumab for HAE: authorization for temporary use in France. Allergy Asthma Clin Immunol 2022; 18:30. [PMID: 35365234 PMCID: PMC8976389 DOI: 10.1186/s13223-022-00664-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/23/2021] [Accepted: 03/03/2022] [Indexed: 11/10/2022]
Abstract
Background Hereditary angioedema (HAE) is associated with a heavy burden of illness. Objective To evaluate use of lanadelumab in a French Authorization for Temporary Use (ATU) program. Methods ATU requests were made between October 12, 2018, and March 13, 2019; patients were followed through September 23, 2019. At entry, patients received lanadelumab 300 mg every 2 weeks. HAE attack characteristics were evaluated at day (D) 0 and months (M) 3 and 6. Patients completed the Angioedema Quality of Life (AE-QoL) questionnaire at initiation and monthly and the Angioedema Activity Score questionnaire daily in 28 day cycles (AAS28). Results In total, 77 patients received ≥ 1 lanadelumab dose; 69 had ≥ 1 quarterly follow-up visit (analyzed population). Mean (standard deviation [SD]) lanadelumab exposure was 240.4 (53.7) days. Lanadelumab dose was modified in 12 patients (mostly to every 4 weeks). For the analyzed population, compared with attacks/month (mean [SD]) within 6 months before ATU (2.68 [2.54]), fewer attacks occurred between initiation and first visit (0.16 [0.42]; P < 0.001) or last visit (0.16 [0.42]; P < 0.001); D15 and last visit (0.15 [0.41]); and D70 and last visit (0.17 [0.70]). AE-QoL total and domain scores were significantly higher at initiation versus M3 and M6; 55% and 65% of patients, respectively, achieved a minimal clinically important difference from D0 to M3 and D0 to M6. Proportion of patients with AAS28 of 0 was higher during M3 (90%) and M6 (83%) than initiation (59%). The most frequently reported adverse events included headache (7.3%) and injection site pain (6.3%). Conclusions Lanadelumab reduced attack rates, improved quality of life, and was generally well tolerated. Supplementary Information The online version contains supplementary material available at 10.1186/s13223-022-00664-4.
Collapse
Affiliation(s)
- Olivier Fain
- service de médecine interne, AP-HP, Hôpital Saint Antoine, Sorbonne Université, 75012, Paris, France.
| | - Aurelie Du-Thanh
- Dermatology Department, Centre Hospitalier Universitaire de Montpellier, Montpellier, France
| | - Delphine Gobert
- service de médecine interne, AP-HP, Hôpital Saint Antoine, Sorbonne Université, 75012, Paris, France
| | - David Launay
- U1286-Infinite-Institute for Translational Research in Inflammation, Department of Internal Medicine and Clinical Immunology, National Reference Centre for Angioedema (CREAK), Inserm, CHU Lille, University of Lille, Lille, France
| | - Neil Inhaber
- Takeda Development Center Americas, Inc, Lexington, MA, USA
| | | | - Magali Aubineau
- Department of Internal Medicine, CHU Edouard Herriot, Lyon, France
| | - Alain Sobel
- Hotel-Dieu de Paris, Université de Paris, Paris, France
| | - Isabelle Boccon-Gibod
- Department of Internal Medicine, National Reference Centre for Angioedema (CREAK), INSERM-CNRS-CEA, CHU Grenoble, Université Grenoble Alpes, Joint Unit, 1036, Grenoble, France
| | | | - Laurence Bouillet
- Department of Internal Medicine, National Reference Centre for Angioedema (CREAK), INSERM-CNRS-CEA, CHU Grenoble, Université Grenoble Alpes, Joint Unit, 1036, Grenoble, France
| |
Collapse
|